欧盟HMA药品数据库（European Union HMA Authorisation of Medicines DataBase）
MR编号DK/H/3243/001
药品名称Cabazitaxel Fresenius Kabi
活性成分
    • Cabazitaxel 20.0 mg/mL
剂型Concentrate for solution for infusion
上市许可持有人Fresenius Kabi AB Rapsgatan 7 751 74 Uppsala Sweden
参考成员国 - 产品名称Denmark (DK)
Cabazitaxel Fresenius Kabi
互认成员国 - 产品名称
    • Netherlands (NL)
      Cabazitaxel Fresenius Kabi 20 mg/ml, Concentraat voor oplossing voor infusie
    • Poland (PL)
      Cabazitaxel Fresenius Kabi
    • Croatia (HR)
    • Luxembourg (LU)
    • Latvia (LV)
    • United Kingdom (Northern Ireland) (XI)
    • Ireland (IE)
    • Lithuania (LT)
      Cabazitaxel Fresenius Kabi 20 mg/ml koncentratas infuziniam tirpalui
    • Austria (AT)
    • Estonia (EE)
    • France (FR)
    • Hungary (HU)
      Cabazitaxel Fresenius Kabi 20 mg/ml koncentrátum oldatos infúzióhoz
    • Spain (ES)
    • Bulgaria (BG)
      Cabazitaxel Fresenius Kabi
    • Portugal (PT)
    • Cyprus (CY)
      CABAZITAXEL FRESENIUS KABI 20MG/ML CONCENTRATE FOR SOLUTION FOR INFUSION
    • Italy (IT)
    • Czechia (CZ)
      Cabazitaxel Fresenius Kabi
    • Greece (GR)
    • Romania (RO)
    • Sweden (SE)
    • Slovakia (SK)
    • Germany (DE)
    • Norway (NO)
    • Slovenia (SI)
    • Belgium (BE)
    • Finland (FI)
    • Malta (MT)
      Cabazitaxel Fresenius Kabi 20 mg/ml concentrate for solution for infusion
许可日期2022/08/03
最近更新日期2025/09/22
药物ATC编码
    • L01CD04 cabazitaxel
申请类型
  • TypeLevel1：Known Active Substance
  • TypeLevel2：Initial Application
  • TypeLevel3：Other Generic application Art 10.3 Dir 2001/83/EC
  • TypeLevel4：Chemical Substance
  • TypeLevel5：Prescription Only
附件文件下载
市场状态Positive
©2006-2025 Drugfuture->European Union HMA Authorisation of Medicines DataBase